A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Conditions
- Obstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic CardiomyopathyHypertrophic Cardiomyopathy
- Interventions
- Registration Number
- NCT03723655
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study.
Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study.
Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 282
- Has completed the Parent Study through to the EOS Visit within 90 days of consent. (Participants who are beyond the 90-day window from EOS Visit may be included in this study pending MyoKardia Medical Monitoring approval) Participants who prematurely discontinued from the Parent Study or the MAVA-LTE study may be considered for inclusion.
- Has a body weight greater than 45 kg at the Screening Visit
- Has adequate acoustic windows to enable accurate TTEs.
- Has documented LVEF ≥ 50% by echocardiography core laboratory read of screening TTE at rest.
- Has safety laboratory parameters (chemistry, hematology, coagulation, and urinalysis) within normal limits (according to the central laboratory reference range).
- Female participants must not be pregnant or lactating and, if sexually active, must use one of the following highly effective birth control methods from the Screening Visit through 90 days after the last dose of investigational medicinal product (IMP).
In addition to the above contraceptive requirements for female participants, male partners must also use a contraceptive (eg. barrier, condom, or vasectomy).
Key
- Has any ECG abnormality considered by the investigator to pose a risk to participant safety (eg. second degree atrioventricular block type II).
- Has a history of syncope or a history of sustained ventricular tachyarrhythmia with exercise between Parent Study EOS Visit and Screening Visit.
- Has a history of resuscitated sudden cardiac arrest or known history of appropriate implantable cardioverter-defibrillator (ICD) discharge for life-threatening ventricular arrhythmia between Parent Study EOS Visit and Screening Visit. (Note: history of anti-tachycardia pacing (ATP) is allowed).• Currently treated with disopyramide or ranolazine (within 14 days prior to Screening) or treatment with disopyramide or ranolazine is planned during the study.
- Has any acute or serious comorbid condition (eg. major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the Investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
- History of clinically significant malignant disease that developed since enrollment in the Parent Study.
- Is unable to comply with the study requirements, including the number of required visits to the clinical site.
- Has participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to Screening, or at least 5 times the respective elimination half-life (whichever is longer), except for participation in MAVERICK-HCM or EXPLORER-HCM. Prior participation in a non-interventional observational study is allowed.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 2 mavacamten Active Treatment for participants with higher target trough concentration Group 1 mavacamten Active Treatment for participants with base target trough concentration Group 3 mavacamten Active Treatment for participants dose titrated to clinical response
- Primary Outcome Measures
Name Time Method Frequency and severity of treatment-emergent adverse events and serious adverse events 252 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (68)
Local Institution - 0023
🇮🇱Safed, Israel
Local Institution - 0036
🇵🇹Almada, Portugal
Local Institution - 0022
🇮🇱Ramat-gan, Israel
Local Institution - 0025
🇮🇱Rehovot, Israel
Local Institution - 0026
🇮🇱Tel Aviv, Israel
Local Institution - 0029
🇳🇱Maastricht, Netherlands
Local Institution - 0032
🇵🇱Warsaw, Poland
Local Institution - 0055
🇺🇸Houston, Texas, United States
Local Institution - 0057
🇺🇸Houston, Texas, United States
Local Institution - 0066
🇺🇸San Francisco, California, United States
Local Institution - 0062
🇺🇸Salt Lake City, Utah, United States
Local Institution - 0044
🇺🇸Portland, Oregon, United States
Local Institution - 0050
🇺🇸Chicago, Illinois, United States
Local Institution - 0046
🇺🇸Philadelphia, Pennsylvania, United States
Local Institution - 0058
🇺🇸Los Angeles, California, United States
Local Institution - 0070
🇺🇸Indianapolis, Indiana, United States
Local Institution - 0053
🇺🇸Charlottesville, Virginia, United States
Local Institution - 0002
🇧🇪Aalst, Belgium
Local Institution - 0048
🇺🇸Saint Louis, Missouri, United States
Local Institution - 0056
🇺🇸New York, New York, United States
Local Institution - 0047
🇺🇸Durham, North Carolina, United States
Local Institution - 0060
🇺🇸New York, New York, United States
Local Institution - 0052
🇺🇸Cincinnati, Ohio, United States
Local Institution - 0071
🇺🇸Charlotte, North Carolina, United States
Local Institution - 0068
🇺🇸Bethlehem, Pennsylvania, United States
Local Institution - 0011
🇩🇰Aarhus, Denmark
Local Institution - 0064
🇺🇸Pittsburgh, Pennsylvania, United States
Local Institution - 0061
🇺🇸Dallas, Texas, United States
Local Institution - 0009
🇨🇿Prague, Czechia
Local Institution - 0072
🇺🇸Murray, Utah, United States
Local Institution - 0010
🇨🇿Praha 2, Czechia
Local Institution - 0016
🇫🇷Paris, France
Local Institution - 0065
🇺🇸Seattle, Washington, United States
Local Institution - 0012
🇩🇰Frederiksberg, Denmark
Local Institution - 0017
🇫🇷Paris, France
Local Institution - 0028
🇮🇹Firenze, Italy
Local Institution - 0013
🇩🇰Odense, Denmark
Local Institution - 0014
🇫🇷Nantes, France
Local Institution - 0015
🇫🇷Toulouse, France
Local Institution - 0018
🇩🇪Dresden, Germany
Local Institution - 0020
🇩🇪Bad Nauheim, Germany
Local Institution - 0030
🇳🇱Rotterdam, Netherlands
Local Institution - 0037
🇪🇸El Palmar, Spain
Local Institution - 0038
🇪🇸A Coruña, Spain
Local Institution - 0042
🇬🇧London, United Kingdom
Local Institution - 0040
🇪🇸Madrid, Spain
Local Institution - 0039
🇪🇸Majadahonda, Spain
Local Institution - 0019
🇩🇪Goettingen, Germany
Local Institution - 0021
🇩🇪Heidelberg, Germany
Local Institution - 0041
🇪🇸Sevilla, Spain
Local Institution - 0067
🇺🇸Jacksonville, Florida, United States
Local Institution - 0063
🇺🇸Stanford, California, United States
Local Institution - 0074
🇺🇸Grand Rapids, Michigan, United States
Local Institution - 0003
🇧🇪Edegem, Belgium
Local Institution - 0027
🇮🇱Jerusalem, Israel
Local Institution - 0024
🇮🇱Petah Tikva, Israel
Local Institution - 0073
🇺🇸Memphis, Tennessee, United States
Local Institution - 0001
🇧🇪Brussels, Belgium
Local Institution - 0033
🇵🇱Katowice, Poland
Local Institution - 0034
🇵🇱Krakow, Poland
Local Institution - 0031
🇵🇱Poznan, Poland
Local Institution - 0035
🇵🇹Lisboa, Portugal
Local Institution - 0054
🇺🇸Boston, Massachusetts, United States
Local Institution - 0045
🇺🇸Scottsdale, Arizona, United States
Local Institution - 0043
🇺🇸New Haven, Connecticut, United States
Local Institution - 0051
🇺🇸Ann Arbor, Michigan, United States
Local Institution - 0059
🇺🇸Richmond, Virginia, United States
Local Institution - 0049
🇺🇸Iowa City, Iowa, United States